Excalipoint Therapeutics Secures $68.7M for Next-Gen TCE Therapies
March 22, 2026, 4:16 am
Excalipoint Therapeutics, a dynamic Shanghai-based biotechnology firm, secured $68.7 million in oversubscribed seed funding. This substantial capital propels its mission to redefine T-cell engager (TCE) therapies. The company is tackling significant challenges in cancer and autoimmune diseases. Funds will drive the advancement of three proprietary technology platforms: TOPAbody, T-Cell Immune Shield, and TCE Probody. A diversified pipeline of six programs, including a Phase I/II candidate, stands ready for accelerated clinical development. This strategic investment highlights global investor confidence in Excalipoint's innovative approach and rapid progress in next-generation immunotherapies. It addresses critical unmet medical needs worldwide.
Excalipoint Therapeutics just secured a substantial $68.7 million in oversubscribed seed funding. This capital infusion significantly boosts the Shanghai-based biotechnology firm. Excalipoint is a leader in next-generation T-cell engager (TCE) therapies. Its core mission targets critical unmet medical needs in oncology and immunology. The company seeks to revolutionize treatments for aggressive cancers and chronic autoimmune diseases.
The robust financing round unfolded in two distinct phases. An initial $41 million powered the company's launch in August 2025. This first tranche saw co-leadership from HSG, Apricot Capital, and Yuanbio Venture Capital. Additional significant participation came from 5Y Capital, Co-Win Ventures, Med-Fine Capital, and Hony Capital. Later, a $27.7 million extension round solidified the investment. MPCi and Centurium Capital expertly co-led this second phase. Key investors Lilly Asia Ventures and Eisai Innovation joined the syndicate. Existing investors also reaffirmed their strong confidence.
This fresh capital injection is vital. It will accelerate the advancement of Excalipoint’s proprietary technology platforms. It also propels its diversified pipeline of therapeutic programs. The overarching objective is clear: improve T-cell immunotherapies. This includes enhancing their efficacy, bolstering safety profiles, and extending therapeutic durability for patients.
Excalipoint confronts long-standing challenges in the field. Current T-cell engager therapies often face significant hurdles. They frequently struggle to activate immune responses in "cold" tumors. The complex tumor microenvironment can suppress therapeutic action. Moreover, targeting specific, challenging tumor antigens remains a formidable task. Excalipoint’s innovative strategies are designed to overcome these fundamental limitations, opening new avenues for treatment.
At the heart of Excalipoint's strategy lie three proprietary platforms. The TOPAbody platform focuses on crafting highly effective tri-specific antibodies. The T-Cell Immune Shield platform aims to judiciously modulate the oppressive tumor microenvironment. The TCE Probody platform (also known as Pro-TCE) enhances the precise targeting of difficult-to-reach tumor antigens. These advanced platforms serve as the technological backbone for Excalipoint's therapeutic breakthroughs. They represent a significant leap in precision medicine.
The company proudly boasts a robust and comprehensive pipeline. Six distinct therapeutic programs are currently under active development. This strategic diversification is crucial. It minimizes single-asset risk. It also positions Excalipoint favorably for future strategic partnerships and licensing opportunities within the global biopharmaceutical landscape.
EXP011 stands as a flagship candidate. This cutting-edge tri-specific antibody targets DLL3, CD3, and 4-1BB simultaneously. It is under development for small cell lung cancer (SCLC), neuroendocrine tumors, and other malignancies that express DLL3. This program has already entered a Phase I/II clinical trial. The first patient was dosed in October 2025, marking rapid clinical progress.
Another highly promising program is EXP012. This tri-specific antibody engages CDH17, CD3, and 4-1BB. Its design targets various gastrointestinal cancers. These include colorectal, gastric, and pancreatic cancers, areas with immense unmet needs.
EXP016 utilizes the innovative TOPAbody platform. This tri-specific antibody focuses on solid tumors. It addresses those conditions with particularly high unmet medical needs, promising a new therapeutic avenue.
EXP017 leverages the sophisticated T-Cell Immune Shield platform. This multi-specific antibody aims to directly tackle key limitations posed by the tumor microenvironment. It seeks to convert non-responsive tumors into treatable ones.
EP101 is developed with the advanced Pro-TCE platform. This molecule is specifically enhanced for superior targeting. It focuses on challenging tumor-associated antigens, often elusive targets for traditional therapies.
Finally, EXP015 broadens Excalipoint’s scope into immunology. This tri-specific antibody, also derived from the TOPAbody platform, targets IgG-associated diseases. This represents a significant move into autoimmune conditions, addressing another vast area of patient need.
Experienced leadership spearheads this rapid advancement. Dr. Lei Fang, a co-founder, serves as Chairman and Chief Executive Officer. Jielun Zhu, also a co-founder, holds the critical roles of Chief Financial Officer and Chief Business Officer. Their combined vision and executive prowess guide Excalipoint's ambitious trajectory.
Excalipoint operates under a unique "China NewCo" model. This innovative framework efficiently merges experienced leadership with substantial capital. It strategically integrates a rich portfolio of pipeline assets. This model significantly accelerates both drug development and subsequent clinical progress. It leverages the strengths of China's burgeoning biotech ecosystem.
The company's rapid expansion is truly remarkable. In just six months since its inception, Excalipoint integrated two additional technology platforms. Its pipeline expanded significantly to encompass six differentiated programs. This swift evolution firmly establishes Excalipoint as a formidable multi-platform biotechnology company. It leads the charge in next-generation immunotherapies globally.
China's robust biotech infrastructure plays a crucial facilitative role. It offers remarkable efficiency in clinical development. It provides unparalleled access to large patient populations. This dynamic environment supports the swift generation of crucial clinical data. It enables the rapid advancement of a diverse range of differentiated therapies, contributing significantly to the global innovation chain.
Excalipoint's strategic vision extends globally. It is dedicated to addressing profound unmet medical needs worldwide. The company's approach masterfully combines rigorous scientific innovation with disciplined execution. This strategy builds a globally competitive biotechnology enterprise. Its advancements hold immense promise for millions suffering from devastating cancers and chronic autoimmune diseases. The substantial investment from top-tier venture capitalists unequivocally validates Excalipoint's scientific foundation and its innovative business model. This positions Excalipoint as a pivotal player in the future of precision medicine.
Excalipoint Therapeutics just secured a substantial $68.7 million in oversubscribed seed funding. This capital infusion significantly boosts the Shanghai-based biotechnology firm. Excalipoint is a leader in next-generation T-cell engager (TCE) therapies. Its core mission targets critical unmet medical needs in oncology and immunology. The company seeks to revolutionize treatments for aggressive cancers and chronic autoimmune diseases.
The robust financing round unfolded in two distinct phases. An initial $41 million powered the company's launch in August 2025. This first tranche saw co-leadership from HSG, Apricot Capital, and Yuanbio Venture Capital. Additional significant participation came from 5Y Capital, Co-Win Ventures, Med-Fine Capital, and Hony Capital. Later, a $27.7 million extension round solidified the investment. MPCi and Centurium Capital expertly co-led this second phase. Key investors Lilly Asia Ventures and Eisai Innovation joined the syndicate. Existing investors also reaffirmed their strong confidence.
This fresh capital injection is vital. It will accelerate the advancement of Excalipoint’s proprietary technology platforms. It also propels its diversified pipeline of therapeutic programs. The overarching objective is clear: improve T-cell immunotherapies. This includes enhancing their efficacy, bolstering safety profiles, and extending therapeutic durability for patients.
Excalipoint confronts long-standing challenges in the field. Current T-cell engager therapies often face significant hurdles. They frequently struggle to activate immune responses in "cold" tumors. The complex tumor microenvironment can suppress therapeutic action. Moreover, targeting specific, challenging tumor antigens remains a formidable task. Excalipoint’s innovative strategies are designed to overcome these fundamental limitations, opening new avenues for treatment.
At the heart of Excalipoint's strategy lie three proprietary platforms. The TOPAbody platform focuses on crafting highly effective tri-specific antibodies. The T-Cell Immune Shield platform aims to judiciously modulate the oppressive tumor microenvironment. The TCE Probody platform (also known as Pro-TCE) enhances the precise targeting of difficult-to-reach tumor antigens. These advanced platforms serve as the technological backbone for Excalipoint's therapeutic breakthroughs. They represent a significant leap in precision medicine.
The company proudly boasts a robust and comprehensive pipeline. Six distinct therapeutic programs are currently under active development. This strategic diversification is crucial. It minimizes single-asset risk. It also positions Excalipoint favorably for future strategic partnerships and licensing opportunities within the global biopharmaceutical landscape.
EXP011 stands as a flagship candidate. This cutting-edge tri-specific antibody targets DLL3, CD3, and 4-1BB simultaneously. It is under development for small cell lung cancer (SCLC), neuroendocrine tumors, and other malignancies that express DLL3. This program has already entered a Phase I/II clinical trial. The first patient was dosed in October 2025, marking rapid clinical progress.
Another highly promising program is EXP012. This tri-specific antibody engages CDH17, CD3, and 4-1BB. Its design targets various gastrointestinal cancers. These include colorectal, gastric, and pancreatic cancers, areas with immense unmet needs.
EXP016 utilizes the innovative TOPAbody platform. This tri-specific antibody focuses on solid tumors. It addresses those conditions with particularly high unmet medical needs, promising a new therapeutic avenue.
EXP017 leverages the sophisticated T-Cell Immune Shield platform. This multi-specific antibody aims to directly tackle key limitations posed by the tumor microenvironment. It seeks to convert non-responsive tumors into treatable ones.
EP101 is developed with the advanced Pro-TCE platform. This molecule is specifically enhanced for superior targeting. It focuses on challenging tumor-associated antigens, often elusive targets for traditional therapies.
Finally, EXP015 broadens Excalipoint’s scope into immunology. This tri-specific antibody, also derived from the TOPAbody platform, targets IgG-associated diseases. This represents a significant move into autoimmune conditions, addressing another vast area of patient need.
Experienced leadership spearheads this rapid advancement. Dr. Lei Fang, a co-founder, serves as Chairman and Chief Executive Officer. Jielun Zhu, also a co-founder, holds the critical roles of Chief Financial Officer and Chief Business Officer. Their combined vision and executive prowess guide Excalipoint's ambitious trajectory.
Excalipoint operates under a unique "China NewCo" model. This innovative framework efficiently merges experienced leadership with substantial capital. It strategically integrates a rich portfolio of pipeline assets. This model significantly accelerates both drug development and subsequent clinical progress. It leverages the strengths of China's burgeoning biotech ecosystem.
The company's rapid expansion is truly remarkable. In just six months since its inception, Excalipoint integrated two additional technology platforms. Its pipeline expanded significantly to encompass six differentiated programs. This swift evolution firmly establishes Excalipoint as a formidable multi-platform biotechnology company. It leads the charge in next-generation immunotherapies globally.
China's robust biotech infrastructure plays a crucial facilitative role. It offers remarkable efficiency in clinical development. It provides unparalleled access to large patient populations. This dynamic environment supports the swift generation of crucial clinical data. It enables the rapid advancement of a diverse range of differentiated therapies, contributing significantly to the global innovation chain.
Excalipoint's strategic vision extends globally. It is dedicated to addressing profound unmet medical needs worldwide. The company's approach masterfully combines rigorous scientific innovation with disciplined execution. This strategy builds a globally competitive biotechnology enterprise. Its advancements hold immense promise for millions suffering from devastating cancers and chronic autoimmune diseases. The substantial investment from top-tier venture capitalists unequivocally validates Excalipoint's scientific foundation and its innovative business model. This positions Excalipoint as a pivotal player in the future of precision medicine.